SNPs in the TGF-β Signaling Pathway Are Associated with Increased Risk of Brain Metastasis in Patients with Non-Small-Cell Lung Cancer

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Li, Qianxia ^a   Wu, Huanlei ^a   Chen, Bei ^c   Hu, Guangyuan ^a   Huang, Liu ^a   Qin, Kai ^a   Chen, Yu ^a   Yuan, Xianglin ^a   Liao, Zhongxing ^b  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c Hubei Provincial Tumor Hospital   (China)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSFORMING GROWTH FACTOR BETA;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BRAIN METASTASIS; CANCER STAGING; FEMALE; FOLLOW UP; GENE; GENE FUNCTION; GENETIC ASSOCIATION; GENOTYPE; HUMAN; INHBC GENE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; METASTASIS POTENTIAL; PREDICTIVE VALUE; RISK ASSESSMENT; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SMAD6 GENE; TGF BETA GENE;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; BRAIN NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; DNA, NEOPLASM; FEMALE; GENOTYPE; HUMANS; INHIBIN-BETA SUBUNITS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; SMAD6 PROTEIN; SURVIVAL RATE; TRANSFORMING GROWTH FACTOR BETA;

EID: 84871262760     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0051713     Document Type: Article

References (37)

1. Bovi JA, White J, (2012) Radiation therapy in the prevention of brain metastases. Curr Oncol Rep 14: 55-62.
2. Subramanian A, Harris A, Piggott K, Shieff C, Bradford R, (2002) Metastasis to and from the central nervous system-the 'relatively protected site'. Lancet Oncol 3: 498-507.
3. Nathoo N, Chahlavi A, Barnett GH, Toms SA, (2005) Pathobiology of brain metastases. J Clin Pathol 58: 237-242.
4. Gore EM, Bae K, Wong SJ, Sun A, Bonner JA, et al. (2011) Phase III comparison of prophylactic cranial irradiation versus observation in patients with locally advanced non-small-cell lung cancer: primary analysis of radiation therapy oncology group study RTOG 0214. J Clin Oncol 29: 272-278.
5. Gaspar LE, Scott C, Murray K, Curran W, (2000) Validation of the RTOG recursive partitioning analysis (RPA) classification for brain metastases. Int J Radiat Oncol Biol Phys 47: 1001-1006.
6. Slotman B, Faivre-Finn C, Kramer G, Rankin E, Snee M, et al. (2007) Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med 357: 664-672.
7. Umsawasdi T, Valdivieso M, Chen TT, Barkley HT Jr, Booser DJ, et al. (1984) Role of elective brain irradiation during combined chemoradiotherapy for limited disease non-small cell lung cancer. J Neurooncol 2: 253-259.
8. Cox JD, Stanley K, Petrovich Z, Paig C, Yesner R, (1981) Cranial irradiation in cancer of the lung of all cell types. JAMA 245: 469-472.
9. Russell AH, Pajak TE, Selim HM, Paradelo JC, Murray K, et al. (1991) Prophylactic cranial irradiation for lung cancer patients at high risk for development of cerebral metastasis: results of a prospective randomized trial conducted by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 21: 637-643.
10. Cox JD, Scott CB, Byhardt RW, Emami B, Russell AH, et al. (1999) Addition of chemotherapy to radiation therapy alters failure patterns by cell type within non-small cell carcinoma of lung (NSCCL): analysis of radiation therapy oncology group (RTOG) trials. Int J Radiat Oncol Biol Phys 43: 505-509.
11. Ceresoli GL, Reni M, Chiesa G, Carretta A, Schipani S, et al. (2002) Brain metastases in locally advanced nonsmall cell lung carcinoma after multimodality treatment: risk factors analysis. Cancer 95: 605-612.
12. Robnett TJ, Machtay M, Stevenson JP, Algazy KM, Hahn SM, (2001) Factors affecting the risk of brain metastases after definitive chemoradiation for locally advanced non-small-cell lung carcinoma. J Clin Oncol 19: 1344-1349.
13. Grinberg-Rashi H, Ofek E, Perelman M, Skarda J, Yaron P, et al. (2009) The expression of three genes in primary non-small cell lung cancer is associated with metastatic spread to the brain. Clin Cancer Res 15: 1755-1761.
14. Massague J, (2008) TGFbeta in Cancer. Cell 134: 215-230.
15. Javelaud D, Alexaki VI, Mauviel A, (2008) Transforming growth factor-beta in cutaneous melanoma. Pigment Cell Melanoma Res 21: 123-132.
16. Nguyen DX, Bos PD, Massague J, (2009) Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer 9: 274-284.
17. Meulmeester E, Ten Dijke P, (2011) The dynamic roles of TGF-beta in cancer. J Pathol 223: 205-218.
18. Khuri FR, Kim ES, Lee JJ, Winn RJ, Benner SE, et al. (2001) The impact of smoking status, disease stage, and index tumor site on second primary tumor incidence and tumor recurrence in the head and neck retinoid chemoprevention trial. Cancer Epidemiol Biomarkers Prev 10: 823-829.
19. Yuan X, Liao Z, Liu Z, Wang LE, Tucker SL, et al. (2009) Single nucleotide polymorphism at rs1982073:T869C of the TGFbeta 1 gene is associated with the risk of radiation pneumonitis in patients with non-small-cell lung cancer treated with definitive radiotherapy. J Clin Oncol 27: 3370-3378.
20. Hildebrandt MA, Yang H, Hung MC, Izzo JG, Huang M, et al. (2009) Genetic variations in the PI3K/PTEN/AKT/mTOR pathway are associated with clinical outcomes in esophageal cancer patients treated with chemoradiotherapy. J Clin Oncol 27: 857-871.
21. Derynck R, Zhang YE, (2003) Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature 425: 577-584.
22. Javelaud D, Alexaki VI, Dennler S, Mohammad KS, Guise TA, et al. (2011) TGF-beta/SMAD/GLI2 signaling axis in cancer progression and metastasis. Cancer Res 71: 5606-5610.
23. Le Page C, Puiffe ML, Meunier L, Zietarska M, de Ladurantaye M, et al. (2009) BMP-2 signaling in ovarian cancer and its association with poor prognosis. J Ovarian Res 2: 4.
24. Lin M, Stewart DJ, Spitz MR, Hildebrandt MA, Lu C, et al. (2011) Genetic variations in the transforming growth factor-beta pathway as predictors of survival in advanced non-small cell lung cancer. Carcinogenesis 32: 1050-1056.
25. McDowell N, Gurdon JB, (1999) Activin as a morphogen in Xenopus mesoderm induction. Semin Cell Dev Biol 10: 311-317.
26. Hully JR, Chang L, Schwall RH, Widmer HR, Terrell TG, et al. (1994) Induction of apoptosis in the murine liver with recombinant human activin A. Hepatology. 20: 854-862.
27. Ball EM, Risbridger GP, (2001) Activins as regulators of branching morphogenesis. Dev Biol 238: 1-12.
28. Jones KL, de Kretser DM, Patella S, Phillips DJ, (2004) Activin A and follistatin in systemic inflammation. Mol Cell Endocrinol 225: 119-125.
29. de Kretser DM, Hedger MP, Loveland KL, Phillips DJ, (2002) Inhibins, activins and follistatin in reproduction. Hum Reprod Update 8: 529-541.
30. Xia Y, Schneyer AL, (2009) The biology of activin: recent advances in structure, regulation and function. J Endocrinol 202: 1-12.
31. Butler CM, Gold EJ, Risbridger GP, (2005) Should activin betaC be more than a fading snapshot in the activin/TGFbeta family album? Cytokine Growth Factor Rev 16: 377-385.
32. Vejda S, Erlach N, Peter B, Drucker C, Rossmanith W, et al. (2003) Expression of activins C and E induces apoptosis in human and rat hepatoma cells. Carcinogenesis 24: 1801-1809.
33. Mellor SL, Ball EM, O'Connor AE, Ethier JF, Cranfield M, et al. (2003) Activin betaC-subunit heterodimers provide a new mechanism of regulating activin levels in the prostate. Endocrinology 144: 4410-4419.
34. Yin J, Lu K, Lin J, Wu L, Hildebrandt MA, et al. (2011) Genetic variants in TGF-beta pathway are associated with ovarian cancer risk. PLoS One 6: e25559.
35. Auperin A, Arriagada R, Pignon JP, Le Pechoux C, Gregor A, et al. (1999) Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. N Engl J Med 341: 476-484.
36. Meert AP, Paesmans M, Berghmans T, Martin B, Mascaux C, et al. (2001) Prophylactic cranial irradiation in small cell lung cancer: a systematic review of the literature with meta-analysis. BMC Cancer 1: 5.
37. Pui CH (2006) Central nervous system disease in acute lymphoblastic leukemia: prophylaxis and treatment. Hematology Am Soc Hematol Educ Program: 142-146.